Floatz logo

APG 115

Malignant Peripheral Nerve Sheath Tumors (MPNST)

Ascentage Pharma Group Inc.Small moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the Malignant Peripheral Nerve Sheath Tumors (MPNST) cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 2B
Fludarabine
St. Jude Children's Research Hospital
Phase 2B
Pembrolizumab
Seattle Children's Hospital
Phase 1/2CCC
Selinexor
Memorial Sloan Kettering Cancer Center
Phase 2CCC
TACROLIMUS
M.D. Anderson Cancer Center
Phase 2CCC

View all 23 →

Same molecule, other indications

APG 115 is also rated in:

T-cell prolymphocytic leukemiaDormant
CCC
Indicative ·
53 / 100
View asset →
non-Hodgkin lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →
High-risk Myelodysplastic SyndromeDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →